Summit Therapeutics Inc. 8-K Filings

Summit Therapeutics Inc. (SMMT) reported that partner Akeso Inc. presented updated overall survival data from the randomized, double-blind Phase III HARMONi-2 trial of ivonescimab versus pembrolizumab in PD-L1–positive advanced non-small cell lung cancer in China.

In the intention-to-treat population of 398 patients and a median follow-up of 36.0 months, ivonescimab monotherapy achieved a median overall survival of 30.8 months versus 22.6 months for pembrolizumab, with an overall survival hazard ratio of 0.73 (95% CI: 0.57–0.95; p=0.009). A notable benefit was seen in the PD-L1 high subgroup (score ≥50%; n=168) with a hazard ratio of 0.58 (95% CI: 0.38–0.89), and positive trends were reported across PD-L1 low and histology subgroups.

Ivonescimab showed an acceptable and manageable safety profile, with serious treatment-related adverse events in 29.9% of ivonescimab patients versus 21.6% on pembrolizumab, and low discontinuation rates in both arms. Akeso received Chinese marketing authorization for ivonescimab in 2025 based on HARMONi-2, while Summit is running multiple global Phase III studies, including the HARMONi-7 trial targeting about 780 patients and a separate HARMONi study that has led to a Biologics License Application accepted by the FDA with a goal PDUFA date of November 14, 2026.

Summit Therapeutics Inc. (SMMT) reported that partner Akeso Inc. announced positive overall survival results from the randomized, double-blind Phase III HARMONi-2 study of ivonescimab monotherapy versus pembrolizumab in PD-L1–positive advanced non-small cell lung cancer in China. Ivonescimab showed a statistically significant overall survival benefit in this preplanned analysis.

Ivonescimab had previously met the primary endpoint of progression-free survival in HARMONi-2, with a hazard ratio of 0.51 (95% CI: 0.38–0.69; p<0.0001), supporting China marketing authorization granted to Akeso in April 2025. Summit highlights a broad late-stage program, including its own positive Phase III HARMONi trial and an accepted Biologics License Application with a goal PDUFA date of November 14, 2026.

Across Summit- and Akeso-sponsored programs, ivonescimab is being studied in multiple Phase III trials in NSCLC and other tumors, with five Phase III trials reported as positive to date and extensive clinical and commercial experience in China. Ivonescimab remains investigational in Summit’s territories, including the United States and Europe.

Summit Therapeutics Inc. (SMMT) reported that its partner Akeso Inc. announced positive topline results from the Phase III HARMONi-GI1 trial in first-line advanced biliary tract cancer. Ivonescimab plus chemotherapy showed statistically significant and clinically meaningful superiority in the primary endpoint of overall survival versus durvalumab plus chemotherapy, and the study also met key secondary endpoints of progression-free survival and objective response rate in a pre-specified interim analysis. HARMONi-GI1 was conducted in China by Akeso, which generated, managed, and analyzed all data; detailed safety and efficacy results are expected at an upcoming medical congress and in a peer-reviewed journal. Ivonescimab (SMT112 in Summit’s territories) remains investigational and is not approved in Summit’s license regions, while a Biologics License Application for ivonescimab in NSCLC based on the HARMONi trial has been accepted by the FDA with a PDUFA goal date of November 14, 2026.

Summit Therapeutics Inc. is expanding its global, registration-enabling development program for ivonescimab into urothelial carcinoma with the initiation of the multi-regional Phase II/III HARMONi-GU1 study. This randomized trial will evaluate ivonescimab plus the antibody-drug conjugate enfortumab vedotin versus pembrolizumab plus enfortumab vedotin as first-line therapy for previously untreated locally advanced or metastatic urothelial carcinoma.

HARMONi-GU1 intends to enroll approximately 800 patients through Phase III, with Phase II identifying the recommended Phase III dose. The primary Phase III endpoints are progression-free survival and overall survival, and global clinical trial site activations are planned to begin by the fourth quarter of 2026. With this study, ivonescimab is being evaluated in 16 Phase III clinical trials across multiple tumor types, alongside a Biologics License Application in NSCLC that has an FDA PDUFA goal date of November 14, 2026.

Summit Therapeutics Inc. entered into a distribution agreement with J.P. Morgan Securities LLC allowing at the market offerings of its common stock with an aggregate offering price of up to $380,000,000. Under this arrangement, J.P. Morgan, as sales agent, may sell shares from time to time at market or negotiated prices and will receive a commission of up to 3.0% of the gross sales price per share. Summit has no obligation to sell shares and may suspend offers at any time. Any issuances will occur under its effective Form S-3 registration statement (File No. 333-296642) and a related prospectus supplement filed on July 23, 2026.

Summit Therapeutics reported Q2 2026 results and progress on its ivonescimab program. GAAP net loss was $215.7 million, or $(0.28) per share, versus $565.7 million, or $(0.76) per share, a year earlier. Non-GAAP net loss was $147.0 million, or $(0.19) per share. Cash, cash equivalents and short-term investments were $690.7 million at June 30, 2026, compared with $713.4 million at December 31, 2025, supported by $230.8 million of Q2 gross proceeds from its ATM facility and a further $68.4 million raised afterward; the company reported no debt.

GAAP operating expenses were $220.5 million in Q2 2026, down from $568.4 million due mainly to lower stock-based compensation, while non-GAAP operating expenses rose to $151.8 million from $89.6 million as ivonescimab development expanded. For the first half of 2026, net cash used in operating activities increased to $263.4 million, partly offset by $234.9 million of cash provided by financing activities.

Summit highlighted ivonescimab as its lead asset. An updated HARMONi overall survival analysis showed a hazard ratio of 0.76 for the intent-to-treat population and for Asian and Western subgroups, with Western patients reaching 23.2 months of median follow-up and Asian patients 32.7 months. The Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated non-squamous non-small cell lung cancer has a Prescription Drug User Fee Act goal action date of November 14, 2026. In China’s HARMONi-6 Phase III trial, ivonescimab plus chemotherapy achieved an overall survival hazard ratio of 0.66 versus tislelizumab plus chemotherapy. Enrollment in the global HARMONi-3 first-line NSCLC study is complete, with key progression-free survival and interim overall survival analyses expected between the second half of 2026 and the first half of 2027. Summit also sold its ridinilazole antibiotic asset to Biossil for $500,000 upfront, up to $104.5 million in milestones, and tiered royalties, and expanded collaborations with Arcus, Revolution Medicines, GORTEC, GSK and multiple investigator-sponsored studies.

Summit Therapeutics Inc. reported updated overall survival results from its global Phase III HARMONi trial of ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone in patients with EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC previously treated with a third‑generation EGFR TKI. The study had already shown a statistically significant benefit in progression‑free survival, one of its two primary endpoints along with overall survival.

With a June 2026 data cut, a hazard ratio of 0.76 for overall survival was observed in both the full intention‑to‑treat population and the western patient subgroup, indicating a favorable survival trend compared with placebo plus chemotherapy. Earlier analyses showed hazard ratios of 0.79 at the April 2025 primary OS analysis and 0.78 at the September 2025 analysis, when median OS was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy. Western follow‑up increased from 9.2 to 13.7 to 23.2 months across these analyses, while Asian patients remained locked at 32.7 months of follow‑up. Ivonescimab continued to show an acceptable, manageable safety profile consistent with prior Phase III data, with no additional safety signals. These updated OS data have been provided to the FDA, where a Biologics License Application based on HARMONi is under review with a PDUFA goal action date of November 14, 2026.

Summit Therapeutics Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected nine directors to serve until the 2027 annual meeting and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of common stock issuable under the plan by 8,000,000 shares, providing additional equity for future grants.

Summit Therapeutics Inc. has withdrawn its previously announced proposed underwritten public offering of securities, effective June 10, 2026, citing market conditions. Because the offering has been terminated, no securities will be sold under that proposed transaction. The update is provided as a Regulation FD disclosure and is not treated as a filed report for liability purposes under Section 18 of the Exchange Act.

Summit Therapeutics Inc. stated that on June 2, 2026, its Audit Committee and all independent directors approved one or more Company affiliates to purchase shares of its common stock through the Company’s previously disclosed at-the-market offering with JP Morgan Securities LLC as Sales Agent.

The Company also noted that Co-CEO and Chairman Robert Duggan, Co-CEO and President Dr. Mahkam Zanganeh, and COO/CFO Manmeet Soni have indicated they are likely to purchase shares under this at-the-market program in the near term. These executives have not specified how many shares they may buy and have made no binding commitments. Any purchases would occur at the prevailing market bid price or better.

Summit Therapeutics reported new clinical data for its investigational bispecific antibody ivonescimab in metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC), highlighted at the 2026 ASCO meeting. In the global Phase II AK112-206 study in first-line unresectable mCRC, ivonescimab plus mFOLFOX6 chemotherapy achieved an objective response rate of 70.8% and a disease control rate of 100.0% in evaluable patients, with a landmark 9‑month progression-free survival rate of 76.1% at the 20 mg/kg dose and an overall acceptable, manageable safety profile.

Separately, Akeso’s China-based Phase III HARMONi-6 trial in first-line advanced squamous NSCLC showed ivonescimab plus platinum chemotherapy reduced the risk of death by 34% versus tislelizumab plus chemotherapy, with an overall survival hazard ratio of 0.66. Median overall survival was 27.89 months for ivonescimab versus 23.69 months for tislelizumab, and 24‑month overall survival rates were 64.7% versus 48.6%, respectively, with a safety profile broadly consistent with prior ivonescimab studies. Ivonescimab is already approved in China but remains investigational in Summit’s territories, where a separate Biologics License Application in NSCLC has been accepted with a PDUFA goal date of November 14, 2026.

Summit Therapeutics Inc. furnished an update on its first quarter ended March 31, 2026, reporting higher spending as it advances ivonescimab through multiple Phase III cancer trials and towards potential approval.

Aggregate cash, cash equivalents, and short-term investments were $598.7 million at March 31, 2026, down from $713.4 million at December 31, 2025, reflecting a quarterly cash burn with net cash used in operating activities of $122.3 million. GAAP operating expenses rose to $195.2 million from $66.8 million a year earlier, driven largely by higher stock-based compensation tied to modified performance-based awards.

GAAP net loss widened to $189.4 million, or $(0.24) per share, versus $62.9 million, or $(0.09), in the prior-year quarter, while non-GAAP net loss, excluding stock-based compensation, was $116.6 million, or $(0.15) per share. The company highlighted progress for ivonescimab, including an accepted Biologics License Application for the HARMONi NSCLC setting with a PDUFA goal date of November 14, 2026 and upcoming HARMONi-6 overall survival data to be featured in an ASCO 2026 Plenary Session.

Summit Therapeutics Inc. reported its fourth quarter and full-year 2025 results and outlined clinical progress centered on ivonescimab, its investigational bispecific PD‑1/VEGF antibody. For 2025, GAAP operating expenses rose to $1,094.4 million, driving a GAAP net loss of $1,079.6 million or $(1.44) per share, largely influenced by $732.4 million of stock-based compensation. On a Non-GAAP basis, operating expenses were $362.0 million and net loss was $347.2 million or $(0.46) per share. Cash, cash equivalents and short-term investments increased to $713.4 million as of December 31, 2025, supported by $617.5 million of financing cash inflows in 2025.

Clinically, the FDA accepted Summit’s Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC, assigning a PDUFA goal action date of November 14, 2026. Key Phase III milestones include an interim progression-free survival analysis for the HARMONi‑3 squamous cohort expected in Q2 2026, with final PFS and interim overall survival in the second half of 2026, and final PFS for the non‑squamous cohort expected in the first half of 2027. Summit also highlighted the planned Phase III ILLUMINE study in PD‑L1 positive head and neck cancer and multiple collaborations and investigator-sponsored trials expanding ivonescimab’s development footprint.

Summit Therapeutics Inc. reported that the U.S. Food & Drug Administration has accepted for filing its Biologics License Application for ivonescimab. The application seeks approval for ivonescimab combined with chemotherapy to treat patients with epidermal growth factor receptor‑mutated, locally advanced or metastatic non‑squamous non‑small cell lung cancer after tyrosine kinase inhibitor therapy.

The FDA set a Prescription Drug User Fee Act goal action date of November 14, 2026, which is the target date for completing its review. Summit disclosed this milestone via a press release, which is included as an exhibit.

Summit Therapeutics Inc. reports a preliminary unaudited balance of approximately $710 million in cash, cash equivalents, and short-term investments as of December 31, 2025, providing a snapshot of its available liquidity.

The company also highlights key business developments: it plans to present at the 44th Annual J.P. Morgan Healthcare Conference, has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval for ivonescimab in combination with chemotherapy for certain epidermal growth factor receptor-mutated non-small cell lung cancer patients, and has entered into a clinical trial collaboration with GSK to study ivonescimab with GSK’s investigational B7-H3 targeting antibody drug conjugate across multiple solid tumors, including small cell lung cancer.

Summit Therapeutics (SMMT) reported that its partner Akeso published final overall survival results from the Phase III HARMONi-A trial in China. The study tested ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone in EGFR‑mutated, locally advanced or metastatic non-squamous NSCLC after EGFR TKI therapy.

Ivonescimab plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit with a hazard ratio of 0.74 (95% CI: 0.58, 0.95; p=0.019). Median OS was 16.8 months (95% CI: 14.5, 20.0) versus 14.1 months (95% CI: 12.8, 16.3) for chemotherapy alone. The analysis used an April 2025 data cut-off and had a 32.5‑month median follow-up. Summit furnished these data via a press release attached as Exhibit 99.1.

Summit Therapeutics Inc. announced a private placement of 26,682,846 shares of common stock at $18.74 per share, matching the October 21, 2025 closing price, for aggregate gross proceeds of approximately $500.0 million. The financing is a primary issuance and is expected to close on or before October 28, 2025, subject to customary closing conditions.

Company leaders and employees participated, purchasing an aggregate of 14,514,402 shares, and Akeso, Inc. purchased 533,617 shares. The shares are being issued in reliance on Section 4(a)(2) and Regulation D exemptions. Summit agreed to file a registration statement to register the resale of these shares as soon as reasonably practicable and no later than December 19, 2025, and to use reasonable best efforts to have it declared effective.

Summit Therapeutics Inc. filed a current report to note that it issued a press release on September 7, 2025 announcing ivonescimab data from its global Phase III HARMONi clinical trial. The data were presented the same day during the Presidential Symposium at the International Association for the Study of Lung Cancer’s 2025 World Conference on Lung Cancer by Jonathan Goldman, MD of UCLA.

The company plans to discuss the ivonescimab HARMONi data on a conference call scheduled for 8:00 a.m. ET on September 8, 2025. The press release is furnished as Exhibit 99.1 and the accompanying presentation slides for the conference call are furnished as Exhibit 99.2.

Summit Therapeutics Inc. disclosed that it furnished a press release announcing its financial results and operational progress for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02.

The filing clarifies that the exhibit is being furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into other Securities Act or Exchange Act filings except by specific reference. The company’s common stock trades under the ticker SMMT on The Nasdaq Stock Market.

Summit Therapeutics amended its distribution agreement with J.P. Morgan Securities LLC to expand its at-the-market capacity, increasing the aggregate amount of common stock it may sell by $360,000,000. The company previously filed a prospectus supplement covering up to $90.0 million of sales, with approximately $45.8 million remaining available under that supplement.

The amendment permits the Sales Agent to sell shares from time to time, including on Nasdaq, to market makers, in block or negotiated transactions, or by other lawful methods, and the Sales Agent will receive a commission of up to 3.0% of gross proceeds. The company is not obligated to sell any shares; any issuance would be pursuant to its effective Form S-3 registration statement and the related prospectus supplements.

Summit Therapeutics Inc. (SMMT) filed an 8-K disclosing that, effective June 16 2025, it entered into a Sub-Sublease Agreement with Ascendis Pharma for approximately 36,406 sq ft of office space in Palo Alto, California.

The lease term runs from January 1 2026 through October 28 2033, spanning nearly eight years. Average annual lease payments are expected to be about $2.8 million, subject to landlord and sub-landlord consent. The full agreement will be filed as an exhibit to the company’s Q2 2025 Form 10-Q.

The filing constitutes an Item 1.01 Material Definitive Agreement disclosure and does not include additional financial or operational updates.